Evans W

Mana Health, 7 Ruskin St, Parnell, Auckland 1052, New Zealand. Electronic address: info@manahealth.co.nz.

11 papers

LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial.

Daldegan-Bueno D, Donegan CJ, Sumner R +11

What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.

Joy Donegan C, Daldegan-Bueno D, Sumner RL +7

LSD microdosing in major depressive disorder: results from an open-label trial.

Daldegan-Bueno D, Donegan CJ, Sumner R +12

Qualitative content analysis of expectations in participants with depression about to begin LSD microdosing treatment: Identifying the need for psychedelic expectancy measures.

Donegan CJ, Daldegan-Bueno D, Noorani T +9

LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder.

Daldegan-Bueno D, Donegan CJ, Forsyth A +16

Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.

Bhagavan C, Glue P, Evans W +8

LSD increases sleep duration the night after microdosing.

Allen N, Jeremiah A, Murphy R +8

PAM trial protocol: a randomised feasibility study of psychedelic microdosing-assisted meaning-centred psychotherapy in advanced stage cancer patients.

Wells A, Muthukumaraswamy APS, Morunga E +10

An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1).

Donegan CJ, Daldegan-Bueno D, Sumner R +15

Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.

Murphy RJ, Sumner R, Evans W +10

MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers.

Murphy RJ, Sumner RL, Evans W +8